Volrustomig Priming Regimens Exploratory Phase II Platform Study

Study summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedVolrustomig and Carboplatin

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 29, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 2

Interventional

Where is it offered?63 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: AstraZeneca
Interventions being studied: Drug: Volrustomig; Drug: Carboplatin; Drug: Pemetrexed; Drug: Ramucirumab; Drug: Paclitaxel

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Key
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
Life expectancy greater than or equal to (\>=) 12 weeks.
Adequate organ and bone marrow function.
Body weight greater than (\>) 35 kilograms (kg) at screening and at randomization.
Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
At least one measurable lesion not previously irradiated that can be accurately measured at baseline as \>= 10 millimeter (mm) in the longest diameter. Key

Reasons someone may not be able to joinExclusion criteria

Spinal cord compression.
History of primary active immunodeficiency.
Active or prior documented autoimmune or inflammatory disorders.
Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (\>) 12 months from end of last therapy.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteLos Angeles, California
Research SiteChapel Hill, North Carolina
Research SiteBeijing
Research SiteHangzhou
Research SiteJinan
Research SiteYantai
Research SiteZhengzhou
Research SiteBois-Guillaume
Research SiteCaen
Research SiteDijon
Research SiteMontpellier
Research SiteBatumi

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 29, 2026. Always confirm current availability with the study team.

View original record ↗